Precision oncology company Lucence today announced a new partnership with experienced laboratory diagnostics distributor Omnigen Medical Products Corporation to expand access of Lucence liquid biopsy tests to cancer patients in Turkey.
Under the terms of the agreement, Omnigen will distribute Lucence’s blood tests to hospitals and clinicians in Turkey. Omnigen is a medical company that provides genetic testing, molecular and pathological equipment in Turkey. Omnigen will liaise with their partner genetic labs to facilitate the logistical coordination as a third party organization.
The available tests include LiquidHALLMARK®, based on proprietary amplicon-based next-generation sequencing (NGS) technology to enable swift treatment decisions for clinicians. The tests will be performed in Lucence’s CLIA-certified, CAP-accredited laboratories.
“NGS tests constitute a large part of the cancer diagnostics market in Turkey. These tests shed light on alternative treatments for patients who do not respond to standard treatment,” said Mr. Ali Kilinc, General Manager and CEO, Omnigen. “Lucence stands at the forefront of innovative diagnostic technology. We are excited to offer Lucence’s precision liquid biopsy tests as an excellent choice for earlier diagnosis and treatment of patients.”
Turkey, a country with 84 million people, saw more than 230,000 new cancer cases in 20201. The most common types are Lung, Breast and Colorectal cancers. Lucence’s LiquidHALLMARK® has been extensively validated2 in these cancer types showing good performance for clinical actionability.
“We are extremely eager to embark on this partnership with Omnigen who is a leading provider of oncology solutions in Turkey at the bridge of Europe and Asia.” said Dr. Min-Han Tan, Founding CEO and Medical Director at Lucence. “Our mission is to serve patients worldwide with quick, reliable and affordable answers for cancer care.”
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
- Poh J, Ngeow KC, Pek M, Tan KH, Lim JS, et al. (2022) Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA. PLOS ONE 17(4): e0267389.